COVID-19

lancet-res-med-lenzilumab-live-air-peer-review.2021.12.01.jpg
lancet-res-med-lenzilumab-indie-expert-comm.2021.12.01.jpg
journal-of-medical-economics-2021.10.08.jpg
ClinicoEconomics and Outcomes Research_edited.jpg
medRxiv-early-lenzilumab-treating-COVID.2022-01.01.jpg
mcp_thumb.png
biorxiv.png
jtm_thumb.png

The Lancet Respiratory Medicine – Peer-Review: Lenzilumab in hospitalised patients with COVID-19 pneumonia (LIVE-AIR): a phase 3, randomised, placebo-controlled trial

The Lancet Respiratory Medicine – Independent Expert Commentary: Lenzilumab in hospitalised patients with COVID-19 pneumonia (LIVE-AIR): a phase 3, randomised, placebo-controlled trial

Journal of Medical Economics: Clinical and economic benefits of lenzilumab plus standard of care compared with standard of care alone for the treatment of hospitalized patients with COVID-19 in the United States from the hospital perspective

ClinicoEconomics and Outcomes Research: Peer-Reviewed Publication Demonstrating the Potential Clinical and Economic Benefits of Lenzilumab from the Perspective of the NHS

bioRxiv: GM-CSF and Cytokine Storm in Coronavirus

Journal of Translational Medicine: The dysregulated innate immune response in severe COVID-19 pneumonia that could drive poorer outcome